NNVC ▼ -0.9% - NanoViricides, Inc. $NNVC - Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo NanoViricides shares declined 0.9% today following news that the company has registered a clinical trial for an oral Ebola treatment in the Pan African Clinical Trials Database as the outbreak in the Democratic Republic of Congo continues to spread. The registration marks progress toward testing the company's candidate therapy, though the modest share decline suggests investors may be weighing the early-stage nature of the trial against the clinical need underscored by the expanding outbreak. 08-SEP-2026 08:30 AM ET